Neurosense Total Current Liabilities from 2010 to 2024
| NRSN Stock | USD 0.86 0.07 7.53% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 3.5 M | Current Value 3.6 M | Quarterly Volatility 1.3 M |
Check Neurosense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurosense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 101.8 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Neurosense financial statements analysis is a perfect complement when working with Neurosense Therapeutics Valuation or Volatility modules.
Neurosense | Total Current Liabilities |
Latest Neurosense Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Neurosense Therapeutics over the last few years. Total Current Liabilities is an item on Neurosense Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neurosense Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Neurosense Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurosense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Neurosense Total Current Liabilities Regression Statistics
| Arithmetic Mean | 660,263 | |
| Geometric Mean | 114,346 | |
| Coefficient Of Variation | 189.77 | |
| Mean Deviation | 911,488 | |
| Median | 37,000 | |
| Standard Deviation | 1,252,999 | |
| Sample Variance | 1.6T | |
| Range | 3.6M | |
| R-Value | 0.72 | |
| Mean Square Error | 809.7B | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 202,252 | |
| Total Sum of Squares | 22T |
Neurosense Total Current Liabilities History
About Neurosense Therapeutics Financial Statements
Neurosense Therapeutics investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Neurosense Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 3.5 M | 3.6 M |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.75 | DYAI | Dyadic International | PairCorr |
| 0.55 | ESPR | Esperion Therapeutics | PairCorr |
| 0.55 | BMY | Bristol Myers Squibb | PairCorr |
| 0.36 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.33 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Neurosense Therapeutics Correlation against competitors. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.